Back

Systemic versus site targeted treatment of neoatherosclerosis.

28 August 2017 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: ESC Grants for Medical Research Innovation Atherosclerosis ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Michael Joner

German Heart Center Muenchen Technical University of Munich, Munich (Germany)

4 More presentations in this session

Presentation thumbnail
Modeling the Individual Risk of Thrombosis in Oncology (MIRTO).
Doctor J. Soria Fernandez (Sant Pau, ES)
Slides Video
Presentation thumbnail
The importance of type of antithrombotic treatment after aortic valve replacement for the risk of future thromboembolic and bleeding events in aortic stenosis - Comparison of mechanical -, bio prosthetic and trans-catheter (TAVI) aortic valve replacement.
Professor C. Christersson (Uppsala, SE)
Slides Video
Presentation thumbnail
Dual approach cardiac MRI for molecular assessment and interventional treatment of vulnerable coronary plaques in a porcine model.
Professor T. Heidt (Buhl, DE)
Slides Video
Presentation thumbnail
Identification of mirRNA profiles associated with venous thromboembolism and recurrent events (IMPROVEMENTS).
Doctor D. Tregouet (Paris, FR)
Slides Video

Access the full session

Session thumbnail
ESC Grants for Medical Research Innovation

The Event

Event poster

ESC Congress 2017

28 August 2017 16:10 CET
You may be interested in
thumbnail
Congress Session
Novel mechanisms for insights into atherosclerosis
26 August 2023
thumbnail
Congress Presentation
Efficacy and safety of local intracoronary drug delivery in the distal coronary bed as treatment of no-reflow phenomenon during percutaneous coronary intervention
27 August 2021
thumbnail
Congress Presentation
The impact of statin treatment intensity after endovascular revascularization for lower extremity peripheral artery disease
27 August 2022
thumbnail
Congress Presentation
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources